Herein, we describe as ynthetic strategy for the regioselective labeling of peptides by using ab ioorthogonal click reaction between 2-cyanobenzothiazole (CBT) and a1 ,2-aminothiol moiety.T his methodology allows for the facile and site-specific modification of peptides with various imaging agents, including fluorophores and radioisotope-containing prosthetic groups.W ei nvestigated the feasibility of an early-stage incorporation of dipeptide 1 into targeting vectors, such as c[RGDyK(C)] and HER2 pep,d uring solid-phase peptides ynthesis. Then, the utility of the click reactiont ol abelb ioactive peptides with aC BT-modified imaging agent (FITC-CBT, 9)w as assessed.T he ligation reaction was found to be highly selective and efficient under various conditions. The fluorescently labeled peptides 2 and 3 were obtainedi nr espective yields of 88 and 82 %under optimized conditions. Low-molecular-weight peptides have received increasing interest as molecular imaging probes and therapeuticsf or cancer.
Herein, we describe as ynthetic strategy for the regioselective labeling of peptides by using ab ioorthogonal click reaction between 2-cyanobenzothiazole (CBT) and a1 ,2-aminothiol moiety.T his methodology allows for the facile and site-specific modification of peptides with various imaging agents, including fluorophores and radioisotope-containing prosthetic groups.W ei nvestigated the feasibility of an early-stage incorporation of dipeptide 1 into targeting vectors, such as c[RGDyK(C)] and HER2 pep,d uring solid-phase peptides ynthesis. Then, the utility of the click reactiont ol abelb ioactive peptides with aC BT-modified imaging agent (FITC-CBT, 9)w as assessed.T he ligation reaction was found to be highly selective and efficient under various conditions. The fluorescently labeled peptides 2 and 3 were obtainedi nr espective yields of 88 and 82 %under optimized conditions. Low-molecular-weight peptides have received increasing interest as molecular imaging probes and therapeuticsf or cancer. [1, 2] Their short blood half-life, low toxicity of degradative products,a nd high specificity for biomolecular targets make them attractive candidates for use as diagnostic agents. [3, 4] Severals hort peptides, such as octreotide and BBN(7-14)a nalogs, have been previously identified as efficient ligandst oi mage overexpressed receptors on tumorc ell surfaces. [5] [6] [7] Incorporation of ar adionuclide or af luorogenic dye into peptides provides the functionality required for cancerd iagnosisu sing real-time, non-invasivei maging technologies, such as positrone missiont omography( PET), single-photon emission computed tomography (SPECT), and fluorescence imaging. [8] [9] [10] For al abeled peptidet ob ee ffective, it must maintain affinity and specificity for its target. The most common strategy to incorporate an imaging agent into ap eptide-based targeting vector is ap ost-synthetic modification ( Figure 1A ). It consists of ad irect-labeling approach mainly based on the side-chain reactivityo fl ysine (Lys) or cysteine (Cys) residues,w here the imaginga gent is coupled to the targeting vectort hrough the formation of either ap eptideb ond, thioether,o rt hiourea linkage. Direct labelingi so ften chosen because it allowsu st o make use of commercially availablep eptides and imaging agents.H owever,t hese conventional conjugationso ften lack regioselectivity.T he functionalized imaging agent( e.g. succinimidyl ester,m aleimide, isothiocyanate) can react with multiple residues and generate am ixture of labeled products with varying yields. Labeling on the bioactive portiono ft he targeting vector may compromisei ts bioactivity and, therefore, tedious purification mayb er equired to isolatet he desired product. [11] Moreover,adistorted stoichiometry,t hat is, nanomolar quantities of the imaging agent versus micromolar amounts of the targeting peptide, is applied to favor the kineticso ft he bioconjugation. [12] Furthermore, the labeling efficiency can be affected by the distribution of the functional groups of the lysine and cysteine residues in the peptide sequence. [13] In some cases,t hese intrinsic residues can become buried within the secondary and tertiary structuralc onformation,r esulting in 2017 The Authors. Published by Wiley-VCH Verlag GmbH &C o. KGaA. This is an openaccessarticleunder the termsoft he Creative Commons Attribution-NonCommercial-NoDerivs License, which permits useand distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. inefficient couplings. [14] Thus, for the successful development of moleculari maging probes, strategies avoiding non-specific labeling must be emphasized.
An alternative strategy to the direct labeling is to functionalize inherentr esidues with ac lickable handle for late-stage labeling ( Figure 1B ). The functionality is used to incorporate an imaging agent through ar apid and chemoselective click reaction. Thiss trategy has been successfully used in the labeling of peptides with sensitive fluorophores or short-lived radionuclides. [15] [16] [17] [18] However,s imilar to the direct-labeling approach, incorporation of the clickable handle is not selective and requires an isolation step prior to the conjugation of the imaging agent. To overcome this criticall imitation, an early-stage incorporation strategy ( Figure 1C )h as been advanced to enable regioselectivel abeling of peptide-based molecular imaging probes. With this method, am olecule functionalized with a clickableh andle is introduced into the peptides equence during the synthesis, followed by the chemoselective ligation of an imaging agent containing the complementary click functionality.T his strategy not only avoids the formationo fm ultilabeled products, but also allows for af lexible design where the click handle is incorporatedo nanon-bioactive region of the peptide, thus preserving its native function.
Synthetic approaches to regioselectively label peptideso ften implement av ariety of click reactions, including the Huisgen cycloaddition (azide/alkyne), Staudinger ligationb etween an azide and phosphite to yield an iminophosphorane, and the inverse electron demandD iels-Alder reaction (tetrazine/trans-cyclooctene). [19] [20] [21] While theses ynthetic routes are viable labeling methods, they requiret he insertion of an on-biogenic functionality in the peptidem otif for the click reaction. Such functional groups are not alwaysc ompatible with reagents used in peptide synthesis (i.e. piperidine andt rifluoroacetic acid). Moreover,t he click reactionm ay involve at oxic metal catalyst, considered too slow for short-lived radionuclides or the click reagents might be quite unstable. Consequently, these reactions may not be the most suitable for the earlystage strategy.
Over the last few years, we studied the naturally occurring 2-cyanobenzothiazole (CBT)/1,2-aminothiolc lick reaction for the labeling of PET imaging probes. [22, 23] The bioorthogonality as well as the high selectivity,m etabolic stability,a nd rapid formation of the resulting luciferin conjugate (approximately three orders of magnitude faster than the Staudinger ligation) makes this synthetic approacha na ttractive option for radiochemistry and for general bioconjugations. [24] [25] [26] [27] Indeed, considering the fragile nature of biomolecules andt he relatively short half-life of some positron-emitting radionuclides ( 18 F, T 1/2 : 109.8 min;
68 Ga, T 1/2 :6 7.6 min), the radiolabeling procedures should be rapid and simple. As such, we envisioned to take advantage of the facile ligation between CBT and an N-terminal cysteine(Cys) residue, which offers an early ideal labeling strategy based on early-stagei ncorporation for peptides. Insertion of the biogenic cysteine amino acid in an on-bioactive portion of the targetingv ector warrants the compatibility with standard solid-phase peptides ynthesis (SPPS)r eactionc onditions and the efficient coupling of the imaging agent.
We describe, herein,t he preparation of peptide-based imaging probesw ith an early-stage incorporation strategy through ar apid CBT/1,2-aminothiolc lick reaction. The scope of this approach was demonstrated throught he labeling of two targeting vectors, ac yclic and al inear peptide, with well-established biological activity.J oshi et al. recently identified ap eptide sequencet hat specifically binds to an extracellular domain of the human epidermal growth factor 2r eceptor (HER2). [6] HER2 is a member of the ErbB tyrosine kinase family,w hichi ss ignificantly overexpressed in many tumors. Al inker containing at erminal lysine residue wasi ntroduced ontot he HER2 binding sequencef or on-resin derivatization of the peptide.Afluorescent probe wasi nstalled on the lysine after selective removal of the N e protecting group. Although this approach enabled selective labeling of the lysine residue, it is not adapted to radioactive labeling. Indeed,d eprotection and cleavage of the peptide from the solid support is done post-labeling, the labeling efficiency is quite low,a nd the reaction time is too long. We instead envisioned thatF moc-Lys-OH could be functionalized with Boc-Cys(Trt)-OSuc to generate Fmoc-Lys(Boc-Cys(Trt))-OH (1)f or use directly in SPPS withoutt he need for foreignr eagentso re xpensive protecting groups in our synthesis of HER2 pep (S4). Analogously,w eapplied this strategy to the synthesis of c[RGDyK(C)] (S3), where the RGD motif is ak nown antagonist of the a v b 3 integrin, at ransmembrane protein that is also overexpressed in malignant tissue. As an initial proofo f concept, we evaluated the kinetics of the CBT/Cys ligationo n these two bioactive peptides with af luorophore functionalized with CBT.W ep ropose that this bioconjugation strategy not only provides maximal versatility and modularity in developing peptide-based imaging probes, but also introduces an ew strategy for pre-targeting imaging and therapy.
Our strategy for the development of the peptide-based targetingp robes 2 and 3 is illustrated in Figure 2 . Preparation of the linear peptide chains was performed by standard Fmoc SPPS. [28] Dipeptide 1 was designed as aF moc-compatible substrate. The acid-labile trityl and tert-butyloxycarbonyl protecting groups on 1 are easily removed in the final cleavage/deprotection step and releasethe 1,2-aminothiol click functionality for subsequent coupling to aC BT-bearing imaging agent. Synthesis of dipeptide 1 is outlined in Scheme 1. Activationo f the carboxylic acid group of commerciallya vailable BocCys(Trt)-OH (4)w as accomplishedt hrough coupling with N-hydroxysuccinimide in the presence of dicyclohexylcarbodiimide (DCC) in ethyl acetate (EtOAc) to yield 5.T he resulting ester 5 was conjugated with Fmoc-Lys-OH in mild basic conditions to produce the CBT-conjugatingb uildingb lock 1 in as atisfying yield of 75 %overthe two steps.
Synthesis of the bioactive peptides c[RGDyK(C)] (S3)a nd HER2 pep (S4)c ontainingd ipeptide 1 werep erformed on an automated synthesizer by following as tandard Fmoc-based SPPS strategy (structures and experimental detailsp rovided in the Supporting Information). [29, 30] In the synthesis of the linear portion of S3,F moc-Gly-OH was selected as the initial residue for loading onto the 2-chlorotrityl chloride solid support (S1) to prevent unwanted C-terminal epimerization during the final cyclization step (Scheme S1). [31] The followingc onjugations yield over the last two steps. S4 was prepared by as imilar Fmoc-based SPPS strategy by using aR ink amide MBHA resin. Preparation of S4 was initiated by loading 1 onto the solid support, followed by as uccessive coupling/deprotection sequencew ith the corresponding Fmoc-protected amino acids. After cleavage, HER2 pep (S4)w as isolated in ay ield of 68 % based on initial resin loading. We next turned our attentiont ot he preparation of the CBTlinked fluorophore 9,o utlined in Scheme 2. Our synthesis was initiated by the O-alkylation of 6-hydroxy-2-cyanobenzothiazole (6)w ith N-Boc-2-bromoethyl-amine under basic conditions to afford the N-Boc-protected CBT 7 in 83 %y ield. Initial attempts to remove the N-Boc protecting group with TFAi nd ichloromethane (DCM)a tr oom temperature wereu nsuccessful. We presumed that alkylation of the cyano moietyw as occurring because of the presence of the tert-butyl cation,f ollowed by at ransformation into N-tert-butylamide side product via hydrolysis. To overcome the degradation of the cyano group 
Scheme2.Preparation of FITC-CBT(9)
. Reagents and conditions: a) N-Boc-2-bromoethyl-amine, NaI, K 2 CO 3 ,acetone,reflux, 24 h, 83 %; b) TFA, thioanisole, DCM, 0 8Ct or t, 4h,9 2%;c )Fluorescein isothiocyanate, DMF,rt, 4h,6 8%.
ChemistryOpen 2018, 7,256 -261 www.chemistryopen.org 2018 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim during deprotection, thioanisole was utilized in the reaction as ac ation scavenger.A fter optimization of the reactionc onditions, the amino derivative 8 was obtainedi n9 2% yield with no indication of degradative product. 8 was then conjugated to fluorescein isothiocyanate (FITC) to produce the FITC-CBT analogue 9 in 68 %y ield.
With the fluorescent probe 9 in hand, we studied the reactivity of CBTd erivatives 6 and 9 against 1,2-aminothiol to form luciferinc onjugates. We first determined the second-order rate constant of the reaction between 6 and l-cysteine by using a high-performance liquid chromatography (HPLC)-based assay. [24] Thea ssay was performed at pH 6.0, 7.4, and 9.0 in phosphate-buffered saline (PBS) and gave rate constants of 0.004, 4. ;F igure S1). [26] The resultsi ndicate that the chemoselective ligation is pH dependent,a sr eactionr ates at neutrala nd basic pH conditions are 1125 and 4650 times higher than the rate of conjugation under slightly acidic conditions. From the mechanisticpoint of view,the thiol group is initially involved in the attack of the CBT cyano group for the formation of the luciferin ring. Our observation implied that the increasing nucleophilicity of the thiol group could accelerate the first step of the cyclization. [32] We then analyzed the second-order kinetics of the reaction between 9 and l-cysteine, which exhibitedarate constanto f 2.1 m À1 s À1 at pH 7.4 in PBS (FigureS2). The data indicate that 6 and 9 have similarr eactivity towards free cysteine. It suggests that modificationa tt he 6p osition has no detrimental effect on the reactivity of CBT.T herefore, it is possible to exploit this positiont od evelop aw ide range of highly reactive CBT-based reagentsf or the bioorthogonal ligation with1 ,2-aminothiol containing molecules for biochemical and pharmacological studies.
To illustrate the applicabilityo fo ur methodology,w ei nvestigated the bioconjugation reaction between 9 and our synthetic peptides. 9 was found to be stable between pH 7.0 and 9.0 in PBS or DMF-containing DIPEA, but completely decomposed at ahigher pH in PBS after 1hincubation at room temperature ( Figure S3) . Thus, the coupling reactions were evaluated in different neutralt os lightly basic conditions. Am ixture of 9 (1.0 equiv) and HER2 pep (1.0 equiv) at pH 7.4 in PBS andi n the presence of tris(2-carboxyethyl)phosphine hydrochloride (TCEP·HCl; 2.0 equiv) was monitored (Table 1, entry 1). As shown in Figure 3 , after 1h at room temperature, the starting material 9 was completely consumed. Formation of FITC-HER2 pep (2)w as observedb yr everse-phase HPLC (RP-HPLC) and confirmed by electrospray ionization mass spectrometry (ESI-MS). The reactionmixture was then purified by RP-HPLC to give 2 in 71 %y ield. Purity of the bioconjugatew as estimated to be higher than 95 %b yH PLC ( Figure S4 ). Next, we evaluated the click reactiona tp H9.0 in PBS. As previously observed with l-cysteine, the reaction of 9 with HER2 pep was faster at pH 9.0 than pH 7.4. To tal consumption of 9 was observeda fter 30 min of reaction, resulting in as imilary ield of 2 (78 %) after purification by RP-HPLC (Table 1 , entry 2). To mimic in vivo conditions,t he reaction was performed in the presence of 10 % human serum in PBS. Despite the complex medium, the bioconjugation reaction was extremely efficient. 2 was isolated with ay ield of 73 %a fter 1hincubation (Table 1, entry 3) . Similar yields were obtained for the CBT/Cys clickr eaction both in the presence or absence of human serum, thereby illustrating the high degree of selectivity of CBT-based reagents towards the N-terminal cysteiner esidue. Importantly,t his highlights the potentialofthis bioorthogonal reaction for in vivoapplications, such as ap re-targeting methodology.T he reaction yields (88 %) werei ncreasedb yu sing DMF as the solventa nd DIPEA as the base (Table 1, entry 4) . This improvement is likely the result of ab etter solubility of 2 in DMF than in aqueous solution. FITC-c(RGDyK) (3)w as synthesized under the optimized conditions (Table 1 , entry 5) in ay ield of 82 %a fter HPLC purification.
We contend that this bioconjugation strategy not only provides maximal versatility and modularity in developing peptide-based theranostic agents, but also introduces an ew strategy for the generationo fi maging or therapeutic conjugates for pre-targetinga pplications in biological systems. The direct application of 1 into routine Fmoc-based SPPS synthesis makes it an ideal candidate for the construction of bioactive peptides that, after resin cleavage and deprotection, will yield ar eactive target molecule that does not require further derivatization prior to conjugationw ith an imaging agent. Moreover, the incorporation of the fluorophore at the 6p ositionofC BT did not hamper its reactivity towards 1,2-aminothiol. It confirms the possibility to functionalize CBT with other imaging agents, including radio-metal chelators for PET or SPECT imaging. To our delight, the bioconjugation proceeded extraordinarily well under biological conditions. Even in the presence of human serum, the specificity and efficiency of the CBT/1,2-aminothiol ligationw as unaltered. Potential of this bioorthogonal cycloaddition for in vivo applicationsh as been highlighted and efforts are underway to optimize the kinetics of the ligationa nd to apply this methodology to the preparation of theranostics by conjugation of ac helator, enabling the coordinationo fa n imaging and at herapeutic radio metal.
Experimental Section General Information
All chemicals were obtained from commercial suppliers and used without further purification. All solvents were anhydrous grade unless indicated otherwise. Hexanes are mixture of isomers. 
HPLC Conditions
The analyses of FITC-labeled CBT or peptides were performed by HPLC on an analytical RP-C18 column (Aqua,P henomenex, 5 mm, 4.6 250 mm) with ag radient elution of acetonitrile (ACN;1 0% to 90 %i nH 2 O, containing 0.1 %T FA)a taflow rate of 1mLmin À1 over 30 min. The products were monitored at 254 nm by aU Vd etector.T he purification of the FITC-labeled peptides was performed on as emi-preparative RP-C18 column (Luna,P henomenex, 5 mm, 10.0 250 mm) at af low rate of 3mLmin À1 over 45 min. The products were monitored at 254 nm by aUVd etector.
Chemical Synthesis
Fmoc-Lys(Boc-Cys(Trt))-OH (1) N-Hydroxysuccinimide (1.35 g, 11.8 mmol) and DCC (2.67 g, 12.9 mmol) were added to as olution of Boc-Cys(Trt)-OH (4)( 5.0 g, 10.7 mmol) in EtOAc (100 mL). The mixture was stirred at room temperature for 24 h. The reaction mixture was filtered off and the solvent layers were concentrated and purified by flash column chromatography (EtOAc/hexanes = 1:4, silica gel) to give 5 as a white solid (6.1 g, 10.8 mmol, quantitative yield). The crude product 5 was directly used for the next step without further purification. Compound 5 (6.1 g, 10.8 mmol) and triethylamine (2.0 mL, 14.3 mmol) were added to as uspension of Fmoc-Lys-OH (4.80 g, 13.0 mmol) in ACN (50 mL) and DMF (50 mL). The reaction mixture was stirred at 40 8C. After stirring for 16 h, the reaction mixture was diluted with EtOAc (200 mL) and washed with 1.0 NH Cl (aq) (2 300 mL) and H 2 O( 2 300 mL). The organic layers were dried over MgSO 4 ,c oncentrated, and purified by column chromatography (EtOAc/hexanes = 2:1, silica gel) to give 1 as aw hite solid (6.5 g, 7.9 mmol, 75 %o ver 2s teps). 1 
FITC-HER2 pep (2)
The HER2 peptide (S4)( 3.3 mg, 2.5 mmol), DIPEA (9.5 mL, 25 mmol) and TCEP·HCl (1.4 mg, 5.0 mmol) were dissolved in DMF (2.0 mL) and incubated for 30 min at room temperature. 9 (1.6 mg, 2.5 mmol) was then added into the above solution, and stirred at room temperature for 1h.T he reaction was monitored and purified by semi-preparative RP-C18 HPLC (retention time, 
FITC-c(RGDyK) (3)
The synthesis of 3 was carried out from S3 (1 mg, 1.4 mmol), as described for the preparation of 2 (yield of 3:1 . 
